In development. Stay tuned.

Feline stomatitis, known as Feline Chronic Gingivostomatitis (FCGS), is an inflammatory disease that occurs in the superficial or deep tissues of the mucosa of the cat's mouth.

The disease is long-lasting, difficult to cure, and prone to recurrence. With a 13.1% probability of developing stomatitis, it is one of the most frequent diseases in cats (second only to dental calculus in prevalence). The exact cause of feline stomatitis is still unknown.

Common symptoms in cats infected with stomatitis are：

• An unpleasant, pungent odor and salivation in the oral cavity.
• White foamy discharge from the corners of the mouth.
• An oral examination will reveal varying degrees of redness and inflammation and tissue growth in the mouth.
• Oral pain can also lead to anorexia in cats, and many cats have even died of starvation alive because they are unable to eat due to severe pain.

 

With current medical resources, once a cat is infected with stomatitis, the pain often lasts a lifetime, and there is no specific treatment. Even with surgical extraction of half or full mouth, 30-40% of cats still cannot be cured.

MT-2073 is an oral small molecule JAK inhibitor. Inhibition of JAK is thought to modulate a variety of cytokines involved in the pathophysiology of feline stomatitis, including interleukin (IL)-4, IL-13, IL-31, and interferon gamma.

Results from a 15-week pivotal clinical study of MT-2073 in the treatment of cats with moderate to moderate stomatitis currently show that the drug met co-primary endpoints and key secondary endpoints related to stomatitis symptom reduction and oral damage repair. In the future, MT-2073 will serve as a heavyweight new drug for MUTIAN that is expected to largely alleviate or even cure this intractable and painful disease in cats.